Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.ChapmanPBHauschildARobertCHaanenJBAsciertoPLarkinJet alImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med20113642507251610.1056/NEJMoa1103782Search in Google Scholar
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.HauschildAGrobJJDemidovLVJouaryTGutzmerRMillwardMet alDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet20123803586510.1016/S0140-6736(12)60868-XSearch in Google Scholar
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): p. 711-23.HodiFSO’daySJMcDermottDFWeberRWSosmanJAHaanenJBet alImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172310.1056/NEJMoa1003466354929720525992Search in Google Scholar
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Eng! J Med 2012; 366: 2443-54.TopalianSLHodiFSBrahmerJRGettingerSNSmithDCMcDermottDFet alSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med20123662443245410.1056/NEJMoa1200690354453922658127Search in Google Scholar
Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies. Eur J Cancer 2016; 53: 125-34.UgurelSRohmelJAsciertoPAFlahertyKTGrobJJHauschildAet alSurvival of patients with advanced metastatic melanoma: the impact of novel therapiesEur J Cancer20165312513410.1016/j.ejca.2015.09.01326707829Search in Google Scholar
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.DaviesHBignellGRCoxCStephensPEdkinsSCleggSet alMutations of the BRAF gene in human cancerNature200241794995410.1038/nature0076612068308Search in Google Scholar
Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, et al. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: patterns of disease progression and clinical management of limited progression. Eur J Cancer 2015; 51: 1435-43.PuzanovIAmaravadiRKMcArthurGAFlahertyKTChapmanPBSosmanJAet alLong-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: patterns of disease progression and clinical management of limited progressionEur J Cancer2015511435144310.1016/j.ejca.2015.04.010508759125980594Search in Google Scholar
Scholtens A, Geukes Foppen MH, Blank CU, van Thienen JV, van Tinteren H, Haanen JB. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression. J Cancer 2015; 51: 642-52.ScholtensAGeukes foppenMHBlankCUvan ThienenJVvan TinterenHHaanenJBVemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progressionJ Cancer20155164265210.1016/j.ejca.2015.01.00925690538Search in Google Scholar
Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013; 31: 1767-74.TrunzerKPavlickACSchuchterLGonzalezRMcArthurGAHutsonTEet alPharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaJ Clin Oncol2013311767177410.1200/JCO.2012.44.788823569304Search in Google Scholar
Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, and Snoj M. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 2008; 34: 232-40.SersaGMiklavcicDCemazarMRudolfZPuciharGSnojMElectrochemotherapy in treatment of tumoursEur J Surg Oncol20083423224010.1016/j.ejso.2007.05.01617614247Search in Google Scholar
Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 2013; 39: 4-16.MaliBJarmTSnojMSersaGMiklavcicDAntitumor effectiveness of electrochemotherapy: a systematic review and meta-analysisEur J Surg Oncol20133941610.1016/j.ejso.2012.08.016Search in Google Scholar
Valpione S, Campana LG, Pigozzo J, Chiarion-Sileni V. Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib. Radiol Oncol 2015; 49: 71-4.ValpioneSCampanaLGPigozzoJChiarion-sileniVConsolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenibRadiol Oncol201549717410.2478/raon-2014-0035Search in Google Scholar
Spector SA, Tyndall M, Kelley E. Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. Am J Med 1982; 73: 36-9.SpectorSATyndallMKelleyEEffects of acyclovir combined with other antiviral agents on human cytomegalovirusAm J Med198273363910.1016/0002-9343(82)90060-2Search in Google Scholar
Hertzman Johansson C, Egyhazi Brage S. BRAF inhibitors in cancer therapy. Pharmacol Ther 2014; 142: 176-82.Hertzman johanssonCEgyhazi brageSBRAF inhibitors in cancer therapyPharmacol Ther201414217618210.1016/j.pharmthera.2013.11.01124325952Search in Google Scholar
Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 2011; 98: 394-9.SambadeMJPetersECThomasNEKaufmannWKKimpleRJShieldsJMMelanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032Radiother Oncol20119839439910.1016/j.radonc.2010.12.017305099721295875Search in Google Scholar
Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, et al. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol 2016; 126: 385-93.DasguptaTOlowAKYangXHashizumeRNicolaidesTPTomMet alSurvival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant gliomaJ Neurooncol201612638539310.1007/s11060-015-1939-2490726426384810Search in Google Scholar
Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 2015; 26: 1238-44.HechtMZimmerLLoquaiCWeishauptCGutzmerRSchusterBet alRadiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsAnn Oncol2015261238124410.1093/annonc/mdv13925762352Search in Google Scholar
Zahnreich S, Mayer A, Loquai C, Grabbe S, Schmidberger H. Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities. Future Oncol 2016; 12: 95-106.ZahnreichSMayerALoquaiCGrabbeSSchmidbergerHRadiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilitiesFuture Oncol2016129510610.2217/fon.15.29726616061Search in Google Scholar
Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, et al. Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. Oncoimmunol 2015; 4: e1008842.MozzilloNSimeoneEBenedettoLCurviettoMGiannarelliDGentilcoreGet alAssessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapyOncoimmunol20154e100884210.1080/2162402X.2015.1008842448575826155423Search in Google Scholar
Brizio M, Fava P, Astrua C, Cavaliere G, Savoia P. Complete regression of melanoma skin metastases after electrochemotherapy plus ipilimumab treatment: an unusual clinical presentation. Eur J Dermatol 2015; 25: 271-2.BrizioMFavaPAstruaCCavaliereGSavoiaPComplete regression of melanoma skin metastases after electrochemotherapy plus ipilimumab treatment: an unusual clinical presentationEur J Dermatol20152527127210.1684/ejd.2015.252226055291Search in Google Scholar
Calvet CY, Famin D, Andre FM, Mir LM. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunol 2014; 3: e28131.CalvetCYFaminDAndreFMMirLMElectrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cellsOncoimmunol20143e2813110.4161/onci.28131411194025083316Search in Google Scholar
Sersa G, Teissie J, Cemazar M, Signori E, Kamensek U, Marshall G, et al. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 2015; 64: p. 1315-27.SersaGTeissieJCemazarMSignoriEKamensekUMarshallGet alElectrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransferCancer Immunol Immunother2015641315132710.1007/s00262-015-1724-2455473526067277Search in Google Scholar
